Compare Amphastar Pharmaceuticals Inc (AMPH) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Visa Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Visa Inc trades at $362.71 (market cap $668.96B). The key difference: Visa Inc is far larger — about 774.3× Amphastar Pharmaceuticals Inc's market cap, and Visa Inc pays a 0.74% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | V | |
|---|---|---|
Market Cap | $863.95M | $668.96B |
Sector | Health | Financials |
52-Week High | $30.81 | $370.47 |
52-Week Low | $16.87 | $295.52 |
Enterprise Value | $1.26B | $679.54B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Visa (V) trades at $362.82, up 0.09% on the day, with strong fundamentals including a 50.78% net income margin and consistent earnings beats. The stock is near-term bearish technically but supported by a bullish analyst consensus with a $426.31 price target. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth amid digital payment evolution.
Visa's outlook remains positive due to robust profitability, strategic tech initiatives, and Wall Street support, though risks include competitive fintech disruption and regulatory pressures. The stock offers long-term growth potential, with current valuation metrics like a P/E of 30.75 reflecting premium pricing justified by its market leadership and earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
